News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Clifford Csizmar: When It Comes to TET2 Mutations in CMML, More are Better
Clifford Csizmar/LinkedIn
Jul 14, 2025, 16:48

Clifford Csizmar: When It Comes to TET2 Mutations in CMML, More are Better

Clifford Csizmar, Hematology and Oncology Fellow (PGY-5) at Mayo Clinic, shared a post on X:

“When it comes to TET2 mutations in CMML, more are better!

Multiple TET2 mt offset the negative impacts of ASXL1 and RAS mutations in myelodysplastic and myeloproliferative CMML, respectively.”

Title: Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.

Authors: Clifford M. Csizmar, Anuya Natu, Mark Gurney, Saubia Fathima, Ali Khalid A. Alsugair, Rashmi Kanagal-Shamanna, Sanam Loghavi, Alexandre Bazinet, Kelly Chien, Danielle Hammond, Courtney DiNardo, Tapan Kadia, Farhad Ravandi-Kashani, Naveen Pemmaraju, Koji Sasaki, Terra L. Lasho, Christy M. Finke, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Naseema Gangat, Mehrdad Hefazi Torghabeh, Aasiya Matin, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop M. Kantarjian, Rami S. Komrokji, Zhuoer Xie, Najla A. Ali, David Sallman, Eric Padron, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Read the Full Article on Leukemia

Clifford Csizmar: When It Comes to TET2 Mutations in CMML, More are Better

More posts featuring TET2 Mutations.

Aasiya Matin Abhishek A Mangaonkar Alexandre Bazinet Ali Khalid A. Alsugair Antoine N Saliba Anuya Natu Aref Al-Kali Ayalew Tefferi cancer Christy M Finke Clifford Csizmar Clifford M Csizmar CMML Courtney DiNardo Danielle Hammond David Sallman Eric Padron Farhad Ravandi-Kashani Guillermo Garcia-Manero Guillermo Montalban-Bravo Hagop M. Kantarjian Hassan Alkhateeb Kebede Begna Kelly Chien Koji Sasaki Mark Gurney Mehrdad Hefazi Torghabeh Mrinal M Patnaik Najla A. Ali Naseema Gangat Naveen Pemmaraju OncoDaily Oncology Rami S Komrokji Rashmi Kanagal-Shamanna Sanam Loghavi Saubia Fathima Tapan Kadia Terra L Lasho Zhuoer Xie
Special Coverage
Blog
Jul 19, 2025, 02:39
Alisher Kahharov: Training at the Prestigious Saint-Louis Hospital in Paris
Blog
Jul 19, 2025, 02:07
Bernard A. Fox: Back in Taiwan - Sharing the Next Frontier in Cancer Immunotherapy at Grand Rounds
Blog
Jul 19, 2025, 02:00
Akash Maniam: How Best to De-Escalate Excellent Responders and Intensify Those Who Don't
Insight
Jul 18, 2025, 21:36
Major disparities in access to Molecular Tumour Boards - Lung Cancer Europe
Oncolibrary
Jul 18, 2025, 21:35
Top 5 AI Tools for Medical Oncologists
Blog
Jul 18, 2025, 20:11
From Lab to Stage: Mastering Research Presentations as a PhD student - Manchester Cancer Research Centre
Blog
Jul 18, 2025, 19:49
Final Call for Discounted Registration to IASLC 2025 World Conference on Lung Cancer
Science
Jul 18, 2025, 19:26
Alfredo Addeo: A True Game Changer in Targeted Therapy for Lung Cancer
Blog
Jul 18, 2025, 19:23
Above and Beyond Awards ceremony at The Institute of Cancer Research
Blog
Jul 18, 2025, 19:04
"Belantamab Mafodotin Gives Patients a Chance," Says Diane Moran - International Myeloma Foundation
Insight
Jul 18, 2025, 18:53
Raffaele Colombo: International Nonproprietary Names Proposed List 133 Is Out
Insight
Jul 18, 2025, 18:46
Akhil Santhosh: OrigAMI1 - The Effect of Amivantamab in Previously Treated RAS Wild Colon Cancer